Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation

New England Journal of Medicine

Volumn 340, Issue 19, 1999, Pages 1462-1470

  Lowance, David ^a   Neumayer, Hans H ^b   Legendre, Christophe M ^c   Squifflet, Jean Paul ^d   Kovarik, Josef ^e   Brennan, Patrick J ^f   Norman, Douglas ^g   Mendez, Rafael ^h   Keating, Michael R ⁱ   Coggon, Gary L ^j   Crisp, Adam ^j   Lee, Ira C ^j  

^a PIEDMONT HOSPITAL   (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e Department of Nephrology   (Austria)

^f HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h National Institute of Transplantation Los Angeles   (United States)

ⁱ MAYO CLINIC   (United States)

^j GLAXOSMITHKLINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

VALACICLOVIR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION PREVENTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACYCLOVIR; ADULT; ANTIVIRAL AGENTS; CADAVER; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; GRAFT REJECTION; HEALTH RESOURCES; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PRODRUGS; SEROLOGIC TESTS; VALINE;

EID: 0033551348     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199905133401903     Document Type: Article

References (40)

1. Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 1990;12:Suppl 7:S754-S766.
2. Ho M. Cytomegalovirus infection and indirect sequelae in the immunocompromised transplant patient. Transplant Proc 1991;23:Suppl 1:2-7.
3. Balfour HH Jr, Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989;320:1381-7.
4. Kletzmayr J, Kotzmann H, Popow-Kraupp T, Kovarik J, Klauser R. Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. J Am Soc Nephrol 1996;7:325-30.
5. Fryd DS, Peterson PK, Ferguson RM, Simmons RL, Balfour HH Jr, Najarian JS. Cytomegalovirus as a risk factor in renal transplantation. Transplantation 1980;30:436-9.
6. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992;53:68-72.
7. Conti DJ, Freed BM, Singh TP, Gallichio M. Gruber SA, Lempert N. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplant recipients. Arch Surg 1995;130:1217-22.
8. Marker SC, Howard RJ, Simmons RL, et al. Cytomegalovirus infection: a quantitative prospective study of three hundred twenty consecutive renal transplants. Surgery 1981;89:660-71.
9. Winston DJ. Prevention of cytomegalovirus disease in transplant recipients. Lancet 1995;346:1380-1.
10. Murray BM. Management of cytomegalovirus infection in solid-organ transplant recipients. Immunol Invest 1997;26:243-55.
11. Pouteil-Noble C, Ecochard R, Landrivon G, et al. Cytomegalovirus infection - an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation 1993;55:851-7.
12. The TH, Grefte JM, van der Bij W, van Son WJ, van den Berg AP. CMV infection after organ transplantation: immunopathological and clinical aspects. Neth J Med 1994;45:309-18.
13. Gulanikar AC, MacDonald AS, Sungurtekin U, Belitsky P. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation 1992;53:323-8.
14. Lindholm A, Ohlman S, Albrechtsen D, Tufveson G, Persson H, Persson N-H. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation 1993;56:307-15.
15. Naimark DMJ, Cole E. Determinants of long-term renal allograft survival. Transplant Rev 1994;8:93.
16. Chatterjee SN, Fiala M, Weiner J, Stewart JA, Stacey B, Warner N. Primary cytomegalovirus and opportunistic infections: incidence in renal transplant recipients. JAMA 1978;240:2446-9.
17. Reusser P. Human cytomegalovirus infection and disease after bone marrow and solid organ transplantation. Baillieres Clin Infect Dis 1996;3: 357-71.
18. Jordan ML, Hrebinko RL, Dummer JS, et al. Therapeutic use of ganciclovir for invasive cytomegalovirus infection in cadaveric renal allograft recipients. J Urol 1992;148:1388-92.
19. Nicholson ML, Veitch PS, Donnelly PK, Flower AJE, Bell PRF. Treatment of renal transplant-associated cytomegalovirus infection with ganciclovir. Transplant Proc 1990;22:1811-2.
20. Dunn DL, Mayoral JL, Gillingham KJ, et al. Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation 1991;51:98-106.
21. Metselaar HJ, Weimar W. Cytomegalovirus infection and renal transplantation. J Antimicrob Chemother 1989;23:Suppl E:37-47.
22. McCarthy JM, Karim MA, Krueger H, Keown PA. The cost impact of cytomegalovirus disease in renal transplant recipients. Transplantation 1993;55:1277-82.
23. Vasquez EM, Sanchez J, Pollak R, Vrahnos D, Fabrega AJ, Maddux MS. High-dose oral acyclovir prophylaxis for primary cytomegalovirus infection in seronegative renal allograft recipients. Transplantation 1993;55: 448-50.
24. Dunn DL, Gillingham KJ, Kramer MA, et al. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. Transplantation 1994;57:876-84.
25. Chitwood KK, Heim-Buthey KL, Ney AL, et al. Questionable benefit of prophylactic acyclovir in renal transplant recipients at high risk for cytomegalovirus disease. Clin Transplant 1993;7:320-4.
26. Saliba F, Eyraud D, Samuel D, et al. Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients. Transplant Proc 1993;25:1444-5.
27. Gavalda J, de Otero J, Murio E, et al. Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients. Transplant Int 1997;10:462-5.
28. Couchoud C, Cucherat M, Haugh M, Pouteil-Noble C. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis. Transplantation 1998;65:641-7.
29. Fletcher CV, Englund JA, Edelman CK, Gross CR, Dunn DL, Balfour HH Jr. Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients. Antimicrob Agents Chemother 1991;35:938-43.
30. Cole NL, Balfour HH Jr. In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir. Diagn Microbiol Infect Dis 1987;6:255-61.
31. Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993;54:595-605.
32. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34: 187-220.
33. Sollinger HW. Mycophenolatc mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995;60:225-32
34. Mayer AD, Dmitrewski J, Squifflet J-P, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cydosporine in the prevention of renal allogrart rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997;64:436-43.
35. Neyts J, Andrei G, De Clercq E. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob Agents Chemother 1998;42:216-22.
36. Wagner JA, Ross H, Hunt S, et al. Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. Transplantation 1995;60:1473-7.
37. Morris DJ. Adverse effects and drug interactions of clinical importance with antiviral drugs. Drug Saf 1994;10:281-91.
38. Candinas D, Keusch G, Schlumpf R, Burger HR, Gmür J, Largiadèr F. Hämolytisch urämisches Syndrom nach Nierentransplantation: prognostische faktoren. Schweiz Med Wochenschr 1994;124:1789-99.
39. Schwarz A, Krause PH, Offermann G, Keller F. Recurrent and de novo renal disease after kidney transplantation with or without cyclosporin A. Am J Kidney Dis 1991;17:524-31.
40. Ramos EL, Tilney NL, Ravenscraft MD. Clinical aspects of renal transplantation. In: Brenner BM, Rector FC Jr, eds. The kidney. 4th ed. Philadelphia: W.B. Saunders, 1991:2361-407.